ClinicalTrials.gg
CompletedNCT04149938Updated Nov 4, 2019

Comparative Pharmacokinetic Study of Lidocaine Patch 1.8% (ZTlido™) and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects

A Phase 1 interventional study of Lidocaine topical system 1.8% and Lidocaine patch 5% in Healthy, sponsored by Scilex Pharmaceuticals, Inc.. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-04.

Sponsored by Scilex Pharmaceuticals, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2016, 10 years ago, and no results have been posted to the registry.
  • Registered 3 years 1 month after the study started (first participant enrolled Sep 2016, registered Oct 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to characterize the comparative single-dose pharmacokinetics (bioequivalence) of lidocaine patch 1.8% (investigational product) versus Lidoderm® (lidocaine patch 5%,reference product).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Scilex Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Must be healthy based on medical history, laboratory work, and physical exam
  • Be ≥18 and ≤65 years of age
  • Females of must not be pregnant and be using an acceptable form of
  • Must be free of any systemic or dermatologic disorder

Key Exclusion Criteria:

  • Use of prescription medication within 14 days or over-the-counter products within 7 days prior to study medication
  • Current use of opioids
  • Known or allergy to any of the components of the product formulations
  • Any serious illness in the 4 weeks preceding the beginning of treatment that resulted in missed work or hospitalization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Lidocaine Patch (Sequence AB)

    Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours.

    Drug: Lidocaine topical system 1.8% · Drug: Lidocaine patch 5%

  • Experimental
    Lidocaine Patch (Sequence BA)

    Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours.

    Drug: Lidocaine topical system 1.8% · Drug: Lidocaine patch 5%

Interventions

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Cmax) of lidocaine

    Peak plasma concentration of lidocaine after application of 3 patches for 12 hours

    Time frame: 0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose

  2. Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time 48 hours

    Area under the plasma concentration versus time curve from 0 to 48 hours of lidocaine in plasma

    Time frame: 0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose

  3. Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time Infinity

    Area under the plasma concentration versus time curve from 0 to infinite time of lidocaine in plamsa

    Time frame: 0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose

  4. Apparent dose

    Apparent dose of delivered lidocaine assessed by calculating the quantity of lidocaine in the patch as manufactured minus the quantity recovered from the used patch after 12 hours of wear and adhesive residue remaining on skin and on the product liner and envelope

    Time frame: 0 to 12 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gudin J, Argoff C, Fudin J, Greuber E, Vought K, Patel K, Nalamachu S. A Randomized, Open-Label, Bioequivalence Study of Lidocaine Topical System 1.8% and Lidocaine Patch 5% in Healthy Subjects. J Pain Res. 2020 Jun 22;13:1485-1496. doi: 10.2147/JPR.S237934. eCollection 2020. PubMed 32606914 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Oct 2016, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2019
First posted
Nov 4, 2019
StartActual
Sep 28, 2016
Primary completionActual
Oct 27, 2016
CompletionActual
Oct 27, 2016
Last update
Nov 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04149938
Lead sponsor
Scilex Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Nov 4, 2019
Start date
Sep 28, 2016
Primary completion
Oct 27, 2016
Completion
Oct 27, 2016
Last update
Nov 4, 2019

Study contacts

Phillip LaStella, MD
principal investigator · TKL Research, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidoderm

Start the discussion